ReviewTherapeutic advances in drug safety2018
Naloxone dosage for opioid reversal: current evidence and clinical implications.
Review in Therapeutic advances in drug safety, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 168 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
168 citing papers in PubMed, 3 syntheses or guidelines pooled it, 338 citations in OpenAlex.
- Management of xylazine toxicity, overdose, dependence, and withdrawal: A systematic review.The American journal on addictions · 2025Pooled it
- Consensus Statement on Pain Management for Pregnant Patients with Opioid-Use Disorder from the Society for Obstetric Anesthesia and Perinatology, Society for Maternal-Fetal Medicine, and American Society of Regional Anesthesia and Pain Medicine.Anesthesia and analgesia · 2025Guideline
- Pooled it
- Take-home naloxone in multicentre emergency settings: the TIME feasibility cluster RCT.Health technology assessment (Winchester, England) · 2024Trial
- Take-home naloxone administered in emergency settings: feasibility of intervention implementation in a cluster randomized trial.BMC emergency medicine · 2024Trial
- A Novel Faster-Acting, Dry Powder-Based, Naloxone Intranasal Formulation for Opioid Overdose.Pharmaceutical research · 2022Trial
- Individual differences in behavioral effects of xylazine and opioid-xylazine mixtures in male rats.Psychopharmacology · 2026Article
- Partially countering the physiological effects of fentanyl with naloxone or d-cysteine ethyl ester in adult goats.Journal of applied physiology (Bethesda, Md. : 1985) · 2026Article
- Pharmacological assessment of drugs retained in the 1Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Sinus Tachycardia Following Administration of Naloxone in a Dog During Anesthetic Recovery.Animals : an open access journal from MDPI · 2026Article
- The effects of vaped cannabis on the severity of naloxone-precipitated opioid withdrawal.Experimental and clinical psychopharmacology · 2026Article
- Modeling Supports Combinatorial Effects Between Pharmacological and Non-Pharmacological Interventions to Prevent Opioid-Induced Cardiac Arrest.Clinical pharmacology and therapeutics · 2026Article
- Dermorphin blocks apneic response to intravenous bolus injection of fentanyl.Toxicology and applied pharmacology · 2026Article
- Biopharmaceutical assessment of naloxone permeation through human respiratory epithelial tissues: A chromatographic-mass spectrometric approach with cloud based aerosol dosing and delivery.Journal of pharmaceutical and biomedical analysis · 2026Article
- Investigating the Landscape of C6-Azaindole Side Chain on the Epoxymorphinan Skeleton via the Nitrogen Walk Concept: A Strategy to Enhance Drug-Like Properties.Journal of medicinal chemistry · 2026Article
- Article
- Comparison of ventilatory depression by carfentanil, fentanyl, and heroin, and reversal by opioid receptor antagonists in rats.Neuropharmacology · 2025Article
- In vitro and in vivo pharmacological characterization of fentanyl analogs.Neuropharmacology · 2025Article
- Combining the alpha-2 adrenergic agonist clonidine with naloxone rescues fentanyl-induced physiologic dysfunction and increases survival.bioRxiv : the preprint server for biology · 2025Article
- Naloxone dosing in the era of synthetic opioids: Applying the Goldilocks principle.Addiction (Abingdon, England) · 2025Review
108 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Opioid-related mortality is a growing problem in the United States, and in 2015 there were over 33,000 opioid-related deaths. To combat this mortality trend, naloxone is increasingly being utilized in a pre-hospital setting by emergency personnel and prescribed to laypersons for out-of-hospital administration. With increased utilization of naloxone there has been a subsequent reduction in mortality following an opioid overdose. Reversal of opioid toxicity may precipitate an opioid-withdrawal syndrome. At the same time, there is a risk of inadequate response or re-narcotization after the administration of a single dose of naloxone in patients who have taken large doses or long-acting opioid formulations, as the duration of effect of naloxone is shorter than that of many opioid agonists. As out-of-hospital use of this medication is growing, so too is concern about effective but safe dosing.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.